4//SEC Filing
STROMATT SCOTT 4
Accession 0001209191-10-052025
CIK 0001298521other
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 6:08 PM ET
Size
15.3 KB
Accession
0001209191-10-052025
Insider Transaction Report
Form 4
STROMATT SCOTT
SVP and Chief Medical Officer
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2010-10-28−27,500→ 0 totalExercise: $1.33Exp: 2018-12-12→ Common Stock (27,500 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2010-10-28−45,000→ 0 totalExercise: $3.82Exp: 2020-01-29→ Common Stock (45,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2010-10-28−25,000→ 0 totalExercise: $1.33Exp: 2019-01-30→ Common Stock (25,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2010-10-28−65,000→ 0 totalExercise: $3.79Exp: 2018-08-29→ Common Stock (65,000 underlying)
Holdings
- 0
Common Stock
Footnotes (4)
- [F1]This option, which provided for vesting as to (a) 12,500 shares on August 29, 2009 and approximtely 1,041 shares monthly thereafter over the following 36 months and (b) the remaining 15,000 shares 1/48th monthly commencing on August 29, 2009, such that all of the shares would be fully vested as of August 29, 2013, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $49,400, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 65,000 contingent value rights, which represents the right to receive possible additional future cash payments.
- [F2]This option, which provided for vesting at the rate of 1/48th on February 1, 2009, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2013, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $80,500, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 25,000 contingent value rights, which represents the right to receive possible additional future cash payments.
- [F3]This option, which provided for vesting at the rate of 1/36th on August 27, 2009, and then 1/36th monthly thereafter, such that all of the shares would be fully vested as of July 27, 2012, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $88,550, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 27,500 contingent value rights, which represents the right to receive possible additional future cash payments.
- [F4]This option, which provided for vesting at the rate of 1/48th on February 1, 2010, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2014, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $32,850, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 45,000 contingent value rights, which represents the right to receive possible additional future cash payments.
Documents
Issuer
Trubion Pharmaceuticals, Inc
CIK 0001298521
Entity typeother
Related Parties
1- filerCIK 0001187053
Filing Metadata
- Form type
- 4
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 6:08 PM ET
- Size
- 15.3 KB